THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Investing dropoff hurting biotechs

Dwindling cash puts jobs at risk

By Scott Kirsner
Globe Correspondent / May 9, 2009

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Three years after Altus Pharmaceuticals Inc. went public and raised $105 million in a single day, the Cambridge biotechnology company is running out of money, and its stock, which once traded for more than $25 a share, closed at 40 cents yesterday. (Full article: 1001 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass